Registration 333-297520
Underwriters: ThinkEquity LLC
Company research
NuvOx Therapeutics, Inc.
CIK 1966126Updated Oct 30, 2026
Filing activity
Latest filing
4 filings on record · S-1/A, S-1.
About the company
We are a clinical-stage biopharmaceutical company developing innovative oxygen therapeutic solutions for the treatment of diseases where hypoxia, or lack of oxygen, plays a critical role. Our product candidate is NanO2, the API of which is dodecafluoropentane. NanO2™ is administered intravenously as an emulsified liquid, containing nano-sized droplets that after entering the body, due to the human body temperature, convert to a gas, which enables them to deliver more oxygen than when in the liquid state. At manufacturing, the size of the NanO2 particle is approximately 30 times smaller in diameter than a red blood cell and approximately 21,000 times smaller in volume than a red blood cell. Compared to red blood cells, NanO2 has the capabilities of enhanced oxygen delivery, more rapid removal of carbon dioxide, and reduction of oxidative stress. Dodecafluoropentane can partition into tissue, deliver oxygen and further facilitate oxygen transfer from red blood cell to tissue.
Recent filings
Offerings
Filing attachments
ea022525708ex4-2_nuvox.htm · S-1 · 2026-07-17
Exhibit 4.2 FORM OF SENIOR CONVERTIBLE PROMISSORY NOTE THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR ANY STATE SECURITIES LAW. THESE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, DISCOUNTED OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED, ENCUMBERED OR IN ANY MANNER DISPOSED OF IN THE ABSENCE OF: (I) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE ACT AND STATE LAWS; OR (II) A ‘NO ACTION’ LETTER…
Read attachment ↗ea022525708ex4-3_nuvox.htm · S-1 · 2026-07-17
Exhibit 4.3 2023 Convertible Promissory Note FORM OF SENIOR CONVERTIBLE PROMISSORY NOTE THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR ANY STATE SECURITIES LAW. THESE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, DISCOUNTED OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED, ENCUMBERED OR IN ANY MANNER DISPOSED OF IN THE ABSENCE OF: (I) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE ACT AND STATE …
Read attachment ↗ea022525708ex4-4_nuvox.htm · S-1 · 2026-07-17
Exhibit 4.4 2024 Convertible Promissory Note FORM OF SENIOR CONVERTIBLE PROMISSORY NOTE THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR ANY STATE SECURITIES LAW. THESE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, DISCOUNTED OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED, ENCUMBERED OR IN ANY MANNER DISPOSED OF IN THE ABSENCE OF: (I) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE ACT AND STATE …
Read attachment ↗ea022525708ex4-5_nuvox.htm · S-1 · 2026-07-17
Exhibit 4.5 December 1, 2025 SUBSCRIPTION AGREEMENT BETWEEN NUVOX THERAPEUTICS, INC. AND PURCHASERS OF SENIOR BRIDGE NOTES OFNUVOX THERAPEUTICS, INC. TOGETHER WITH ACCOMPANYING WARRANTS * * * FOR ACCREDITED INVESTORS ONLY * * * THE SENIOR, CONVERTIBLE, UNSECURED PROMISSORY NOTES AND WARRANTS (THE “WARRANTS”) OF NUVOX THERAPEUTICS, INC. (“COMPANY”) (OR ANY SUCCESSOR ENTITY) SUBSCRIBED TO UNDER THIS AGREEMENT, AND THE SECURITIES INTO WHICH THE NOTES ARE CONVERTIBLE INTO UPON THE OCCURRENC…
Read attachment ↗ea022525708ex4-6_nuvox.htm · S-1 · 2026-07-17
Exhibit 4.6 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION REQUIREMENTS OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONA…
Read attachment ↗ea022525708ex4-7_nuvox.htm · S-1 · 2026-07-17
Exhibit 4.7 AMENDMENT TO SUBSCRIPTION AGREEMENTS AND NOTES This Amendment To Subscription Agreement and Notes (this “ Amendment ”) is entered into by and among NuvOx Therapeutics, Inc., a Delaware corporation (the “ Company ”), NuvOx Pharma, LLC (the “ LLC ”), an Arizona corporation and a wholly-owned subsidiary of the Company, and the purchaser parties hereto, effective as of June 25, 2026. Reference is made to (i) that certain Amended & Restated 2021 Senior Convertible Promissory Note Subscr…
Read attachment ↗